Multiple-biomarker Approach for Individualized Treatment of Heart Failure with Preserved Ejection Fraction

Launched by ERASMUS MEDICAL CENTER · Jan 20, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how changes in certain blood markers can help predict health outcomes for people with heart failure that preserves its pumping ability, known as Heart Failure with Preserved Ejection Fraction (HFpEF). By tracking these markers over time, researchers hope to create a more personalized and accurate way to manage this condition. The study is currently recruiting participants aged 18 and older who have been diagnosed with HFpEF based on specific guidelines.

To be eligible for the trial, participants must understand and agree to join the study. However, certain health conditions may prevent someone from participating, such as having a very low heart function, needing surgery soon, or serious kidney or liver problems. If someone joins, they can expect regular check-ups and tests to monitor their health and the blood markers. Overall, this trial aims to improve treatment for heart failure patients by finding better ways to predict their health needs.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age of 18 years or older
• • Capable of understanding and signing informed consent
• • A diagnosis of HFpEF according to the HFA-PEFF diagnostic algorithm of the ESC or/and a high (90%) probability of HFpEF according to the H2FPEF score, i.e. a score of 6 or higher.
• Exclusion Criteria:
• • History of LVEF ≤40%
• • Scheduled for surgery or intervention for both coronary and non-coronary indication within 6 months of inclusion
• • Impaired renal function, defined as eGFR \< 20 mL/min/1.73 m2 (CKD-EPI) or requiring dialysis at the time of screening
• • Acute or chronic liver disease, defined by serum levels of transaminases or alkaline phosphatase more than three times the upper limit of normal at screening
• • COPD Gold stage IV
• • Congenital heart disease
• • Pregnancy
• • Coexistent condition with life expectancy of \<1 year
• • Unlikely to appear at all scheduled follow-up visits
• • Linguistic barrier